MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 19, ...

MannKind Corporation (NASDAQ:MNKD) is one of the 11 Best US Stocks to Invest in Under $5. MannKind Corporation (NASDAQ:MNKD) ...

MannKind to Present at Upcoming Investor Conferences. DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the ...

What:Shareholders of inhaled insulin maker MannKind Corporation are having a rough day. The company's stock is down more than 26% as of 12:30 p.m. EST Tuesday after MannKind reported its first ...

It took 10 years and $1 billion for MannKind Corp. in Valencia to get its breakthrough inhaled-insulin drug approved by U.S. regulators.

Hours after MannKind Corp. announced on Tuesday that Sanofi had pulled out of an agreement to license its Afrezza inhaled insulin, a MannKind executive said the Valencia company does not plan to ...

MannKind Corporation beats analysts on earnings and revenue in Q2 2023, with a year-over-year increase of 157.3% in revenue. Strong demand for Afrezza and Tyvaso DPI contributes to revenue growth.

What happened Shares of MannKind Corporation (NASDAQ: MNKD) were down 13.9% as of 3:31 p.m. EDT on Monday. The drop followed a 23% plunge on Friday.

Since the Food and Drug Administration's approval of its inhaled insulin product, Afrezza, in 2014, MannKind Corporation (NASDAQ: MNKD) has lost a staggering 90% of its value. And the company now ...

What happened Shares of MannKind Corporation (NASDAQ: MNKD) are soaring today, up 43% as of 9:35 a.m. EDT, following news that the company has struck.

MannKind taps investors for some much-needed capital. Shares of MannKind Corporation (NASDAQ: MNKD), the maker of inhaled insulin product Afrezza, are down by 15.3% in pre-market trading today on ...